Navi raises $6.8m to bring neonatal catheter device to US

By Takeshi Mori · 2026-08-02

A line in the wrong place

Central venous catheters are a cornerstone of neonatal intensive care. Clinicians thread these lines into the smallest patients imaginable every day, delivering fluids, nutrition and medication directly into the bloodstream. Get the tip placement wrong and the consequences cascade: bloodstream infections, thrombosis, organ perforation, repeat imaging, line replacements. Published research puts the misplacement rate at roughly one in three in newborns when traditional surface-major and X-ray confirmation methods are used.^[3]

The underlying problem is architectural. ECG-guided catheter placement systems are standard kit in adult ICUs across the United States, but they were engineered for adult vessel diameters and adult heart rates. A neonate is not a small adult, and tiny vessels combined with rapid heart rhythms render adult-calibrated signals unreliable, leaving paediatric clinicians to fall back on post-procedure X-rays that delay treatment and expose fragile patients to ionising radiation.

What Neonav actually does

Melbourne-based Navi Medical Technologies built the Neonav ECG Tip Location System from the ground up for neonatal and paediatric patients. The device combines real-time intravascular ECG tip location with continuous migration surveillance, giving clinicians precise placement confirmation at insertion and ongoing positional monitoring after the line is in. That second function matters: catheter tips migrate as infants grow and move, and no adult-oriented system was tracking that in real time.

Chief Executive Officer Alex Newton said neonatal and paediatric clinicians have long relied on technologies never designed for their smallest patients.^[1] Navi operates from both Melbourne and Boston, a dual-geography structure that reflects where the engineering originated and where the commercial opportunity now sits.

The raise: size, structure and who backed it

Navi closed a A$6.8 million capital raise on 29 July 2026, led by ANZ healthcare venture capital firm KP Rx, which contributed A$4 million of the total.^[1] Innovation Victoria and Pacific Channel also participated. Newton said the capital will go directly into scaling manufacturing, growing the US team and deepening partnerships with leading children's hospitals.^[1]

KP Rx Partner Hashan De Silva said the firm backed Navi on the strength of both the technology and the team's execution record. De Silva said Navi has developed a genuinely differentiated technology addressing a real unmet clinical need, and that the company has shown strong execution from product development through to FDA clearance and early engagement with leading US children's hospitals.^[1]

Bushletter notes that the financial figures and investor participation details in this article come from Navi's own company release and have not been independently verified by a third-party source. The FDA clearance date and clearance status are verifiable through public regulatory channels.

The regulatory inflection point

The Neonav ECG Tip Location System received US FDA 510(k) clearance on 17 February 2025, authorising its use in American hospitals to enhance neonatal and paediatric vascular access care.^[3] That clearance arrived roughly 18 months after the company's previous funding round and unlocked the pathway to commercial sales in the world's largest medical device market.

Navi has since commenced clinical evaluations at two leading US children's hospitals, according to the company, though the names of those institutions have not been disclosed.^[1] Commercial sales in US hospitals are expected to begin in 2026, with the July raise providing the operational capital to make that timeline viable.

Trajectory: from A$2.4m seed to US market entry

Navi is not a first-raise story. In August 2023 the company closed a A$2.4 million round that included a A$700,000 lead investment from Breakthrough Victoria, capital it used to advance Neonav development toward the regulatory submissions that would follow.^[2] The July 2026 raise brings total disclosed funding to over A$9.2 million.

The US addressable market is large. Published context from the company's own materials puts the annual volume of central line placements in newborn and paediatric patients in the United States above one million, representing what Navi describes as a multi-hundred-million-dollar opportunity.^[3] Those figures are company-reported and Bushletter has not verified them independently.

Newton said the new capital positions Navi to execute on the commercial opportunity its regulatory clearance opened, allowing the company to scale manufacturing, grow its US team and partner with leading children's hospitals as it works to establish a new standard of care in neonatal and paediatric vascular access.^[1] Neonav's first paying US hospital customer will be the clearest measure of whether that timeline holds.

Takeshi Mori

Takeshi Mori writes about technology and start-ups. He is curious about how products get built and who they are really for, and he would rather see a thing working than hear it described.